Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-omics microbiome mechanisms of differential response to secukinumab in moderate-to-severe psoriasis
ChiCTR2500101048Phase 4Not yet recruiting
- Sponsor
- Southern Medical University Shenzhen Hospital
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of secukinumab in psoriasis, sponsored by Southern Medical University Shenzhen Hospital. Primary endpoints: Blood routine index, Microbiological indicator and 1 more. Planned start Apr 2025; status: not yet recruiting.
02
Drugs
secukinumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on ChiCTR2500101048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500101048.